Results 51 to 60 of about 3,026 (154)
Antibiotics, 2023 Clostridioides difficile infection (CDI) is a significant cause of morbidity and mortality, mostly in frail patients. Notification is not mandatory in Italy, and data on incidence, risk of death, and recurrence are lacking.
Alice Annalisa Medaglia +13 more
doaj +1 more source
Evaluating Effects of Antibiotics Across Preclinical Models of the Human Gastrointestinal Microbiota
MicrobiologyOpen, Volume 14, Issue 4, August 2025.We compared microbiota changes following antibiotic treatment in two preclinical models of the human GI microbiota, minibioreactor arrays (MBRAs) and human microbiota associated mice (HMAmice). MBRAs and HMAmice were colonized with feces from 12 or 3 healthy humans, respectively, before treatment with each of 12 or 6 antibiotics.
Thomas A. Auchtung +3 more
wiley +1 more source
High‐Throughput Tiling of Essential mRNAs Increases Potency of Antisense Antibiotics
Advanced Science, Volume 12, Issue 28, July 24, 2025.The systematic tiling of essential genes’ mRNA here presented, proposes a valuable tool for the identification of novel PNA sequences with antibiotic potential. The high‐throughput synthetic set up opens the door to investigating thousands of sequences in an economic way and ultimately identifies potent antisense oligonucleotides while also giving room
Giorgia Danti +3 more
wiley +1 more source
The Kaohsiung Journal of Medical Sciences, Volume 41, Issue 5, May 2025.ABSTRACT Clostridioides difficile infection (CDI) worsens the prognosis of patients with inflammatory bowel disease (IBD). This retrospective cohort study aimed to evaluate the risk factors, clinical manifestations, and outcomes of CDI in hospitalized patients with IBD, including those with toxin A/B results between April 2007 and April 2021.
Puo‐Hsien Le +10 more
wiley +1 more source
Fidaxomicin inhibits toxin production in Clostridium difficile [PDF]
Journal of Antimicrobial Chemotherapy, 2012 Fidaxomicin, which was recently approved for the treatment of Clostridium difficile-associated diarrhoea, demonstrates narrow-spectrum bactericidal activity via inhibition of RNA polymerase. In this study we evaluated its inhibitory activity versus C. difficile toxin gene expression and toxin production by quantifying toxin mRNA and protein.The effects
Farah, Babakhani +5 more
openaire +2 more sources
Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy
MedComm, Volume 6, Issue 5, May 2025.ABSTRACT Dysbiosis refers to the disruption of the gut microbiota balance and is the pathological basis of various diseases. The main pathogenic mechanisms include impaired intestinal mucosal barrier function, inflammation activation, immune dysregulation, and metabolic abnormalities.
Yao Shen +5 more
wiley +1 more source
APMIS, Volume 133, Issue 5, May 2025.ABSTRACT Studies focusing on young adults with Clostridiodes (formerly Clostridium) difficile infection (CDI) are scarce. Our objective was to assess characteristics and outcomes of CDI among hospitalized young adults between the ages of 18–45 years at diagnosis, compared to a subcohort of randomly selected older patients aged > 45 years.
Borisz Rabán Petrik +7 more
wiley +1 more source
Antibiotics, 2017 Lipiarmycin A3 and tiacumicin B possess the same chemical structure and have been considered identical till recently, when some authors have suggested the possibility of a minor difference between the chemical structures of the two antibiotics.
Stefano Serra +4 more
doaj +1 more source
Fidaxomicin Inhibits Spore Production in Clostridium difficile [PDF]
Clinical Infectious Diseases, 2012 Fidaxomicin (FDX) is a novel antimicrobial agent with narrow-spectrum and potent bactericidal activity against Clostridium difficile. In recent clinical trials, FDX was superior to vancomycin in preventing recurrences of C. difficile infection. A possible mechanism of reducing recurrence may be through an inhibitory effect on sporulation. The effect of
Babakhani, Farah +5 more
openaire +2 more sources
Transplant Infectious Disease, Volume 27, Issue 3, May/June 2025.Prophylactic oral vancomycin was associated with reduced Clostridium difficile infection in allogeneic stem cell transplant patients. No differences in hospital‐acquired infections, mortality, GVHD, or rehospitalization were observed. It is a low‐cost, effective preventative strategy, though further prospective studies are needed to confirm safety and ...
Brendon Fusco +8 more
wiley +1 more source